Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
Lal AP, Foong YC, Sanfilippo PG, Spelman T, Rath L, Levitz D, Fabis-Pedrini M, Foschi M, Habek M, Kalincik T, Roos I, Lechner-Scott J, John N, Soysal A, D'Amico E, Gouider R, Mrabet S, Gross-Paju K, Cárdenas-Robledo S, Moghadasi AN, Sa MJ, Gray O, Oh J, Reddel S, Ramanathan S, Al-Harbi T, Altintas A, Hardy TA, Ozakbas S, Alroughani R, Kermode AG, Surcinelli A, Laureys G, Eichau S, Prat A, Girard M, Duquette P, Hodgkinson S, Ramo-Tello C, Maimone D, McCombe P, Spitaleri D, Sanchez-Menoyo JL, Yetkin MF, Baghbanian SM, Karabudak R, Al-Asmi A, Jakob GB, Khoury SJ, Etemadifar M, van Pesch V, Buzzard K, Taylor B, Butzkueven H, Van der Walt A. Lal AP, et al. Among authors: kalincik t. J Neurol. 2024 Sep;271(9):5813-5824. doi: 10.1007/s00415-024-12518-7. Epub 2024 Jun 27. J Neurol. 2024. PMID: 38935148 Free PMC article.
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis.
Kalincik T, Spelman T, Trojano M, Duquette P, Izquierdo G, Grammond P, Lugaresi A, Hupperts R, Cristiano E, Van Pesch V, Grand'maison F, La Spitaleri D, Rio ME, Flechter S, Oreja-Guevara C, Giuliani G, Savino A, Amato MP, Petersen T, Fernandez-Bolanos R, Bergamaschi R, Iuliano G, Boz C, Lechner-Scott J, Deri N, Gray O, Verheul F, Fiol M, Barnett M, van Munster E, Santiago V, Moore F, Slee M, Saladino ML, Alroughani R, Shaw C, Kasa K, Petkovska-Boskova T, den Braber-Moerland L, Chapman J, Skromne E, Herbert J, Poehlau D, Needham M, Bacile EA, Arruda WO, Paine M, Singhal B, Vucic S, Cabrera-Gomez JA, Butzkueven H; MSBase Study Group. Kalincik T, et al. PLoS One. 2013 May 21;8(5):e63480. doi: 10.1371/journal.pone.0063480. Print 2013. PLoS One. 2013. PMID: 23704913 Free PMC article. Clinical Trial.
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.
Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M, Izquierdo G, Lugaresi A, Grand'maison F, Hupperts R, Oreja-Guevara C, Bergamaschi R, Iuliano G, Alroughani R, Van Pesch V, Amato MP, Slee M, Verheul F, Fernandez-Bolanos R, Fiol M, Spitaleri DL, Cristiano E, Gray O, Cabrera-Gomez JA, Shaygannejad V, Herbert J, Vucic S, Needham M, Petkovska-Boskova T, Sirbu CA, Duquette P, Girard M, Grammond P, Boz C, Giuliani G, Rio ME, Barnett M, Flechter S, Moore F, Singhal B, Bacile EA, Saladino ML, Shaw C, Skromne E, Poehlau D, Vella N, Spelman T, Liew D, Kilpatrick TJ, Butzkueven H; MSBase Study Group. Kalincik T, et al. Brain. 2013 Dec;136(Pt 12):3609-17. doi: 10.1093/brain/awt281. Epub 2013 Oct 18. Brain. 2013. PMID: 24142147
Fingolimod after natalizumab and the risk of short-term relapse.
Jokubaitis VG, Li V, Kalincik T, Izquierdo G, Hodgkinson S, Alroughani R, Lechner-Scott J, Lugaresi A, Duquette P, Girard M, Barnett M, Grand'Maison F, Trojano M, Slee M, Giuliani G, Shaw C, Boz C, Spitaleri DL, Verheul F, Haartsen J, Liew D, Butzkueven H; MSBase Study Group. Jokubaitis VG, et al. Among authors: kalincik t. Neurology. 2014 Apr 8;82(14):1204-11. doi: 10.1212/WNL.0000000000000283. Epub 2014 Mar 7. Neurology. 2014. PMID: 24610329 Free PMC article.
Risk of relapse phenotype recurrence in multiple sclerosis.
Kalincik T, Buzzard K, Jokubaitis V, Trojano M, Duquette P, Izquierdo G, Girard M, Lugaresi A, Grammond P, Grand'Maison F, Oreja-Guevara C, Boz C, Hupperts R, Petersen T, Giuliani G, Iuliano G, Lechner-Scott J, Barnett M, Bergamaschi R, Van Pesch V, Amato MP, van Munster E, Fernandez-Bolanos R, Verheul F, Fiol M, Cristiano E, Slee M, Rio ME, Spitaleri D, Alroughani R, Gray O, Saladino ML, Flechter S, Herbert J, Cabrera-Gomez JA, Vella N, Paine M, Shaw C, Moore F, Vucic S, Savino A, Singhal B, Petkovska-Boskova T, Parratt J, Sirbu CA, Rozsa C, Liew D, Butzkueven H; MSBase Study Group. Kalincik T, et al. Mult Scler. 2014 Oct;20(11):1511-22. doi: 10.1177/1352458514528762. Epub 2014 Apr 28. Mult Scler. 2014. PMID: 24777276
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.
Kalincik T, Jokubaitis V, Izquierdo G, Duquette P, Girard M, Grammond P, Lugaresi A, Oreja-Guevara C, Bergamaschi R, Hupperts R, Grand'Maison F, Pucci E, Van Pesch V, Boz C, Iuliano G, Fernandez-Bolanos R, Flechter S, Spitaleri D, Cristiano E, Verheul F, Lechner-Scott J, Amato MP, Cabrera-Gomez JA, Saladino ML, Slee M, Moore F, Gray O, Paine M, Barnett M, Havrdova E, Horakova D, Spelman T, Trojano M, Butzkueven H; MSBase Study Group. Kalincik T, et al. Mult Scler. 2015 Aug;21(9):1159-71. doi: 10.1177/1352458514559865. Epub 2014 Dec 5. Mult Scler. 2015. PMID: 25480857
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H; MSBase Study Group. Kalincik T, et al. Ann Neurol. 2015 Mar;77(3):425-35. doi: 10.1002/ana.24339. Epub 2015 Jan 17. Ann Neurol. 2015. PMID: 25546031 Clinical Trial.
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Girard M, Pucci E, Iuliano G, Alroughani R, Oreja-Guevara C, Fernandez-Bolaños R, Grand'Maison F, Sola P, Spitaleri D, Granella F, Terzi M, Lechner-Scott J, Van Pesch V, Hupperts R, Sánchez-Menoyo JL, Hodgkinson S, Rozsa C, Verheul F, Butzkueven H, Kalincik T; MSBase Study Group. He A, et al. Among authors: kalincik t. JAMA Neurol. 2015 Apr;72(4):405-13. doi: 10.1001/jamaneurol.2014.4147. JAMA Neurol. 2015. PMID: 25665031 Free article.
Comparative efficacy of switching to natalizumab in active multiple sclerosis.
Spelman T, Kalincik T, Zhang A, Pellegrini F, Wiendl H, Kappos L, Tsvetkova L, Belachew S, Hyde R, Verheul F, Grand-Maison F, Izquierdo G, Grammond P, Duquette P, Lugaresi A, Lechner-Scott J, Oreja-Guevara C, Hupperts R, Petersen T, Barnett M, Trojano M, Butzkueven H. Spelman T, et al. Among authors: kalincik t. Ann Clin Transl Neurol. 2015 Apr;2(4):373-87. doi: 10.1002/acn3.180. Epub 2015 Feb 27. Ann Clin Transl Neurol. 2015. PMID: 25909083 Free PMC article.
232 results